Celcuity (CELC)
NASDAQ:CELC
CELC Stock Chart & Stats
$117.14
-$0.35(-2.63%)
At close: 4:00 PM EST
$117.14
-$0.35(-2.63%)
Day’s Range― - ―
52-Week Range$9.02 - $125.00
Previous CloseN/A
Volume14.25K
Average Volume (3M)726.29K
Market Cap
$5.66B
Enterprise Value$5.69B
Total Cash (Recent Filing)$441.50M
Total Debt (Recent Filing)$195.38M
Price to Earnings (P/E)―
Beta0.41
Next Earnings
May 18, 2026EPS Estimate
-1.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.97
Shares Outstanding48,336,674
10 Day Avg. Volume652,927
30 Day Avg. Volume726,291
Financial Highlights & Ratios
PEG Ratio-0.88
Price to Book (P/B)52.11
Price to Sales (P/S)0.00
P/FCF Ratio-34.13
Enterprise Value/Market Cap1.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-70.27K
Enterprise Value/Ebitda-37.60
Forecast
1Y Price Target
$121.17Price Target Upside3.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-3.91
Revenue Forecast (FY)$55.30M
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And TolerabilityPivotal trial data showing extended progression-free survival for gedatolisib combinations in the wild-type cohort, paired with improved tolerability and fewer severe treatment-related side effects, strengthen the drug's clinical profile versus earlier studies.
Commercial Preparedness And Cash RunwayManagement reports sufficient cash and short-term investments and has built much of the commercial infrastructure, while positive feedback from physicians and payers supports potential uptake and reduces near-term financing risk.
Regulatory ProgressFDA acceptance of the New Drug Application with Priority Review and Real-Time Oncology Review status shortens regulatory timelines and increases the chance of a quicker assessment for potential approval.
Bears Say
Competition And Financing PressureHigh short interest, ongoing cash burn, and the prospect of competing against large pharmaceutical firms with established commercial networks increase both financing and commercial execution risk.
Readout And Timing UncertaintyUncertainty around database lock timing and the high-stakes PIK3CA-mutant cohort readout, together with the risk of an FDA decision delay, could produce sharp stock volatility if timing or results diverge from expectations.
Valuation And Downside RiskStock appears priced for perfection for a pre-revenue company with a single asset, creating substantial downside risk if clinical or regulatory outcomes fall short of expectations.
Celcuity News
CELC FAQ
What was Celcuity’s price range in the past 12 months?
Celcuity lowest stock price was $9.02 and its highest was $125.00 in the past 12 months.
What is Celcuity’s market cap?
Celcuity’s market cap is $5.66B.
When is Celcuity’s upcoming earnings report date?
Celcuity’s upcoming earnings report date is May 18, 2026 which is in 36 days.
How were Celcuity’s earnings last quarter?
Celcuity released its earnings results on Mar 25, 2026. The company reported -$0.97 earnings per share for the quarter, beating the consensus estimate of -$1.042 by $0.072.
Is Celcuity overvalued?
According to Wall Street analysts Celcuity’s price is currently Undervalued.
Does Celcuity pay dividends?
Celcuity does not currently pay dividends.
What is Celcuity’s EPS estimate?
Celcuity’s EPS estimate is -1.04.
How many shares outstanding does Celcuity have?
Celcuity has 48,336,674 shares outstanding.
What happened to Celcuity’s price movement after its last earnings report?
Celcuity reported an EPS of -$0.97 in its last earnings report, beating expectations of -$1.042. Following the earnings report the stock price went up 4.164%.
Which hedge fund is a major shareholder of Celcuity?
Currently, no hedge funds are holding shares in CELC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Celcuity Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$121.17 (3.44% Upside)
$121.17 (3.44% Upside)
Blogger Sentiment
Bullish
CELC Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 1.1%
Last 30 Days ▲ 0.8%
Last 30 Days ▲ 0.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
1254.21%
12-Months-Change
Fundamentals
Return on Equity
-203.17%
Trailing 12-Months
Asset Growth
90.34%
Trailing 12-Months
Company Description
Celcuity
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.
CELC Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong clinical and regulatory momentum centered on potentially practice-changing Phase III data for the wild-type cohort, an accepted NDA with Priority Review and supporting peer-reviewed publication, plus active commercial preparation and a solid cash runway. These positives are balanced against materially higher operating losses, rising R&D and G&A spend tied to the commercial launch, increased operating cash burn, and limited near-term disclosure around the mutant cohort readout. On balance, the transformative clinical/regulatory progress and commercial positioning materially outweigh the financial burn and execution risks, which appear expected for a company transitioning to potential commercialization.View all CELC earnings summariesCELC Stock 12 Month Forecast
Average Price Target
$121.17
▲(3.44% Upside)
Technical Analysis
―
IDEAYA Biosciences
―
Tarsus Pharmaceuticals
―
Belite Bio, Inc. ADR
―
Apogee Therapeutics
―